Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 May;34(5):931–933. doi: 10.1128/aac.34.5.931

Sucralfate significantly reduces ciprofloxacin concentrations in serum.

J C Garrelts 1, P J Godley 1, J D Peterie 1, E H Gerlach 1, C C Yakshe 1
PMCID: PMC171725  PMID: 2360833

Abstract

The effect of sucralfate on the bioavailability of ciprofloxacin was evaluated in eight healthy subjects utilizing a randomized, crossover design. The area under the concentration-time curve from 0 to 12 h was reduced from 8.8 to 1.1 micrograms.h/ml by sucralfate (P less than 0.005). Similarly, the maximum concentration of ciprofloxacin in serum was reduced from 2.0 to 0.2 micrograms/ml (P less than 0.005). We conclude that concurrent ingestion of sucralfate significantly reduces the concentrations in serum produced by a 500-mg dose of ciprofloxacin. On the basis of these findings, ciprofloxacin and sucralfate should not be administered concurrently.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brittain D. C., Scully B. E., McElrath M. J., Steinman R., Labthavikul P., Neu H. C. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. J Clin Pharmacol. 1985 Mar;25(2):82–88. doi: 10.1002/j.1552-4604.1985.tb02806.x. [DOI] [PubMed] [Google Scholar]
  2. Brumfitt W., Franklin I., Grady D., Hamilton-Miller J. M., Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):757–761. doi: 10.1128/aac.26.5.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Garnett W. R. Sucralfate--alternative therapy for peptic-ulcer disease. Clin Pharm. 1982 Jul-Aug;1(4):307–314. [PubMed] [Google Scholar]
  4. Gonzalez M. A., Uribe F., Moisen S. D., Fuster A. P., Selen A., Welling P. G., Painter B. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984 Nov;26(5):741–744. doi: 10.1128/aac.26.5.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Haram E. M., Weberg R., Berstad A. Urinary excretion of aluminium after ingestion of sucralfate and an aluminium-containing antacid in man. Scand J Gastroenterol. 1987 Jun;22(5):615–618. doi: 10.3109/00365528708991908. [DOI] [PubMed] [Google Scholar]
  6. Nix D. E., Watson W. A., Handy L., Frost R. W., Rescott D. L., Goldstein H. R. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin. Pharmacotherapy. 1989;9(6):377–380. doi: 10.1002/j.1875-9114.1989.tb04152.x. [DOI] [PubMed] [Google Scholar]
  7. Pai S., Melethil S., Cuddy P., Hall T. Elevation of serum aluminum in humans on a two-day sucralfate regimen. J Clin Pharmacol. 1987 Mar;27(3):213–215. doi: 10.1002/j.1552-4604.1987.tb02187.x. [DOI] [PubMed] [Google Scholar]
  8. Parpia S. H., Nix D. E., Hejmanowski L. G., Goldstein H. R., Wilton J. H., Schentag J. J. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother. 1989 Jan;33(1):99–102. doi: 10.1128/aac.33.1.99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Robertson J. A., Salusky I. B., Goodman W. G., Norris K. C., Coburn J. W. Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis. Ann Intern Med. 1989 Jul 15;111(2):179–181. doi: 10.7326/0003-4819-111-2-179. [DOI] [PubMed] [Google Scholar]
  10. Weber A., Chaffin D., Smith A., Opheim K. E. Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1985 Apr;27(4):531–534. doi: 10.1128/aac.27.4.531. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES